Kajikawa Akinobu, Igimi Shizunobu
Department of Food, Bioprocessing, & Nutrition Sciences, North Carolina State University, 341 Schaub Hall, North Carolina State University, Raleigh, NC 27695, USA.
Division of Biomedical Food Research, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Biosci Microflora. 2011;30(4):93-8. doi: 10.12938/bifidus.30.93. Epub 2011 Nov 17.
Many Lactobacillus and Lactococcus strains are generally regarded as safe for consumption because they are utilized for food fermentation or inhabit the intestinal mucosa as commensals. Recently, vaccine delivery systems using lactic acid bacteria (LAB) have been under development. Our research group has been investigating the development of oral mucosal vaccines against Salmonella enterica serovar Enteritidis (SE) using Lactobacillus casei IGM393 as an antigen delivery vehicle. Recombinant lactobacilli expressing SE antigens, FliC, SipC, and OmpC, have been constructed and orally administered to mice. Antigen specific immune responses and protective immunity were elicited after the immunization. For adjuvant-delivery, IL-1β-secreting L. casei was also engineered and its effects evaluated in vitro and in vivo. This article reviews a novel approach to the elimination of Salmonella via the development of a vaccine in lactobacilli.
许多乳酸杆菌和乳球菌菌株通常被认为食用安全,因为它们被用于食品发酵或作为共生菌栖息在肠道黏膜中。最近,使用乳酸菌(LAB)的疫苗递送系统一直在研发中。我们的研究小组一直在研究以干酪乳杆菌IGM393作为抗原递送载体开发针对肠炎沙门氏菌肠炎血清型(SE)的口服黏膜疫苗。已经构建了表达SE抗原FliC、SipC和OmpC的重组乳杆菌,并将其口服给予小鼠。免疫后引发了抗原特异性免疫反应和保护性免疫。为了递送佐剂,还构建了分泌IL-1β的干酪乳杆菌,并在体外和体内评估了其效果。本文综述了一种通过开发乳杆菌疫苗来消除沙门氏菌的新方法。